Skip to main content

Market Overview

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Share:
Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has enrolled the first patient in the new Phase 3 RESILIENT study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia.

  • An interim analysis by an Independent Data Monitoring Committee of the first 50% of enrolled patients for a potential sample size readjustment or early stop for futility is expected in Q1 of 2023.
  • In December 2020, Tonix reported positive results from the first Phase 3 study (RELIEF) of TNX-102 SL 5.6 mg to manage fibromyalgia.
  • Several secondary measures in RELIEF highlighted the broad effects of TNX-102 SL across several cardinal symptoms of fibromyalgia beyond pain. 
  • In March 2022, Tonix reported the results of a subsequent Phase 3 study (RALLY) in which TNX-102 SL did not achieve statistical significance on the primary endpoint (p=0.115). 
  • Relative to the RELIEF study, RALLY had an unexpected increase in study participant adverse event-related discontinuations in both the drug and placebo groups.
  • Fibromyalgia is a pain disorder characterized by chronic widespread pain, non-restorative sleep, fatigue, and impaired cognition.
  • Price Action: TNXP shares are up 7.48% at $0.23 during the market session on the last check Thursday.
 

Related Articles (TNXP)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com